Every topic opens with a quick approach, then the red flags that change the plan, then the sources behind it. Filter by subcategory or open the full approach for the detail.
Dysmorphic
22q11.2 Deletion Syndrome
The most common microdeletion syndrome: conotruncal cardiac defects, palatal anomalies, hypocalcaemia, immune deficiency and a high risk of psychiatric illness later in life.
Recognise the cluster: interrupted aortic arch or tetralogy of Fallot, velopharyngeal insufficiency, hypocalcaemia, recurrent infection and learning differences.
Confirm the deletion with a targeted 22q11.2 study or a chromosomal microarray.
Screen for associations: calcium, lymphocyte subsets and renal ultrasound, plus cardiac and palate assessment.
Plan the long game: developmental, educational and psychiatric follow-up into adulthood.
Red flags
Neonatal hypocalcaemic seizures
Conotruncal cardiac defect in a newborn
Absent thymus or severe T-cell lymphopenia
Cleft palate with feeding difficulty
First-episode psychosis in a young adult with learning differences
The commonest skeletal dysplasia, caused by FGFR3 gain-of-function variants, with rhizomelic short stature, macrocephaly and a normal-length trunk.
Confirm the phenotype: rhizomelic short limbs, macrocephaly, frontal bossing and a normal trunk.
Confirm genetically with FGFR3 testing — almost all cases carry the same Gly380Arg variant.
Screen for complications: foramen magnum imaging, sleep studies, head circumference and growth monitoring.
Counselling and referral: a multidisciplinary skeletal dysplasia service and discussion of vosoritide eligibility.
Red flags
Foramen magnum stenosis with apnoea, feeding difficulty or desaturation
Hydrocephalus or head circumference crossing centiles
Severe thoracolumbar kyphosis or new spinal cord signs
Obstructive sleep apnoea in early childhood
The commonest chromosomal syndrome, caused by trisomy 21, with characteristic facial features, hypotonia and variable intellectual disability along with a defined pattern of health problems.
Confirm the diagnosis with a karyotype or chromosomal microarray.
Screen the newborn for congenital heart disease and duodenal atresia before the first discharge.
Arrange hearing and vision checks and thyroid function in the first months.
Watch for atlantoaxial instability if there is new weakness, neck pain or a gait change.
Link the family to early support and a coordinated health-supervision schedule.
Red flags
Any newborn with hypotonia and dysmorphic features
Signs of congenital heart disease or duodenal atresia
New regression, neck pain or a gait change suggesting atlantoaxial instability
Dystrophin deficiency causes progressive proximal weakness in boys, with a raised creatine kinase from birth, calf pseudohypertrophy and loss of independent walking in the second decade. Early recogni
Measure creatine kinase first in any boy with delayed walking, a Gowers sign or calf pseudohypertrophy; it is markedly raised long before weakness is obvious.
Confirm with dystrophin gene testing including deletion and duplication analysis.
Start glucocorticoids between 4 and 8 years, before motor decline begins.
Set the surveillance rhythm: annual cardiac and respiratory review, bone health and vaccination checks.
Offer family testing for carrier status and prenatal options to the mother and at-risk relatives.
Red flags
Creatine kinase above 10 times the upper limit of normal
Gowers sign or toe walking in a boy aged 2 to 5
Unexplained cardiomyopathy in a young male
Markedly raised transaminases of unknown cause
A CGG repeat expansion in FMR1 causes the commonest inherited cause of intellectual disability and autism. Expansion size predicts the phenotype and identifies carriers at risk of premature ovarian in
Test FMR1 repeat size for unexplained intellectual disability, autism, or a family history of either; a standard sequencing panel does not answer this question.
Interpret the repeat: premutation 55 to 200 repeats, full mutation above 200 with methylation analysis.
Screen associated features: mitral valve prolapse, seizures, recurrent otitis media and macroorchidism.
Offer carrier testing to relatives and discuss premutation risks, including fragile X-associated premature ovarian insufficiency and FXTAS.
Arrange early support: developmental, speech and behavioural input as soon as the diagnosis is made.
Red flags
Unexplained intellectual disability or autism with a positive family history
Premature ovarian insufficiency in a woman under 40
Late-onset intention tremor and ataxia in an older adult
A mother with a premutation and repeated pregnancy loss
Pathogenic BRCA1 and BRCA2 variants drive most hereditary breast and ovarian cancer. Referral follows early-onset or triple-negative breast cancer, ovarian cancer at any age, male breast cancer, and m
Confirm the phenotype: record age at diagnosis, receptor status, histology, laterality and any male breast cancer.
Map a three-generation pedigree covering breast, ovarian, prostate, pancreatic and male breast primaries.
Check testing eligibility against current NCCN or local thresholds before ordering a multi-gene panel.
Classify every variant with ACMG and AMP criteria, and never act on a variant of uncertain significance.
Close the loop: route a positive result to surveillance, risk-reducing options and cascade testing of relatives.
Red flags
Breast cancer before age 45
Triple-negative breast cancer before age 60
Ovarian, tubal or peritoneal carcinoma at any age
Male breast cancer at any age
Two or more close relatives with breast or ovarian cancer
inborn errors of metabolism in the ED, NICU and PICU
A bedside reference for suspected inborn errors of metabolism in the ED, NICU and PICU: triage, the critical sample, reversing catabolism and the first-pattern differential.
First actions: assess airway, breathing, circulation and neurologic status. Check bedside glucose immediately, establish IV/IO access, and treat shock and seizures. Evaluate and treat possible sepsis in parallel. Call metabolic genetics and PICU early for encephalopathy, rising ammonia, severe acidosis or refractory hypoglycaemia.
Collect a critical sample: if feasible before treatment, draw glucose, blood gas, electrolytes with anion gap, ammonia, lactate, beta-hydroxybutyrate, liver panel and INR. Send plasma amino acids, acylcarnitines and free/total carnitine, plus urine organic acids and ketones.
Reverse catabolism: for severe hypoglycaemia give 10% dextrose 2 mL/kg IV, then a glucose infusion or appropriate feeds. Calculate the actual glucose infusion rate: GIR (mg/kg/min) = dextrose % x rate (mL/hr) / [6 x weight (kg)].
Work the pattern: high ammonia with respiratory alkalosis suggests a urea-cycle disorder; high anion gap with ketosis suggests an organic acidaemia; hypoglycaemia with inappropriately low ketones suggests a fatty-acid oxidation defect or hyperinsulinism; hypoglycaemia with hepatomegaly and lactate suggests hepatic glycogen storage disease
Red flags
Check bedside glucose immediately in any acutely unwell child. Encephalopathy, rising ammonia, severe acidosis or refractory hypoglycaemia: call metabolic genetics and PICU early. Treat shock, seizures and possible sepsis in parallel - in a sick child, treatment takes priority over the critical sample.
A germline TP53 variant confers multi-organ, early-onset cancer risk: sarcomas, premenopausal breast cancer, adrenocortical carcinoma, brain tumours and leukaemia. A diagnosis changes surveillance for
Suspect it when a sarcoma appears before 45, adrenocortical carcinoma at any age, or early breast cancer alongside another TP53-spectrum tumour.
Test correctly: use a multi-gene panel that includes TP53 with full deletion and duplication analysis.
Screen the family with whole-body MRI plus dedicated breast MRI, and avoid unnecessary ionising radiation.
Counsel broadly: discuss reproductive options and cascade testing for first- and second-degree relatives.
Red flags
Sarcoma before 45 years
Adrenocortical carcinoma at any age
Choroid plexus carcinoma in childhood
Breast cancer before 35 years
Two TP53-spectrum tumours in the same patient
FBN1-related connective tissue disorder with aortic root dilatation, ectopia lentis, long-bone overgrowth and dural ectasia. Dissection risk drives management, so recognition and serial imaging matter
Score against the revised Ghent nosology: aortic root Z-score, ectopia lentis, systemic score and family history.
Order FBN1 sequencing with deletion and duplication analysis, and keep overlapping aortopathies in mind.
Image the aorta at baseline and then serially according to growth rate.
Start beta-blockade or an ARB when the aortic root is dilated, and counsel on exercise restriction.
Refer onward: ophthalmology assessment and genetic counselling of relatives.
Red flags
Aortic root Z-score of 2 or higher
Acute chest or back pain in a patient with a known or suspected aortopathy
Ectopia lentis on slit lamp examination
Family history of sudden death at a young age
Progressive lysosomal storage disorders caused by defects in glycosaminoglycan degradation. Recognition, enzyme and molecular testing, subtype-specific therapy, and the surveillance and perioperative
Recognise the pattern: multisystem disease with coarse facial features, hernias, hepatosplenomegaly, recurrent ENT disease, snoring or obstructive sleep apnoea, valvular disease, joint stiffness and dysostosis multiplex. Early developmental plateau or regression with somatic features suggests severe MPS I or neuronopathic MPS II; speech delay then behavioural and sleep problems and regression suggests MPS III. Skeletal-predominant disease with disproportionate short stature and cervical instability suggests MPS IV.
Test in parallel: send urinary GAGs with age-adjusted interpretation plus GAG fractionation or a targeted disaccharide profile by LC-MS/MS where available, and choose enzyme assays from the pattern. Confirm with enzyme activity in leukocytes or cultured fibroblasts and targeted molecular or panel testing. A low dried blood spot result needs diagnostic follow-up, and enzyme, substrate and variant results must correlate to separate disease from pseudodeficiency.
Treat by subtype: laronidase 0.58 mg/kg IV weekly (MPS I) with early HSCT evaluation for severe MPS I; idursulfase 0.5 mg/kg IV weekly for somatic MPS II; elosulfase alfa 2 mg/kg IV weekly (MPS IVA); galsulfase 1 mg/kg IV weekly (MPS VI); vestronidase alfa 4 mg/kg IV every 2 weeks (MPS VII). MPS III is supportive care, with Fayuvi gene therapy FDA-approved for neurologic MPS IIIA with preserved function.
Surveil every system: cardiology with ECG and echocardiogram; ENT, respiratory and polysomnography; spine and mobility with cervical instability and cord compression assessment; audiology and ophthalmology; growth, development, adaptive skills and school function. Tailor intervals to subtype, age and treatment.
Plan for sedation and surgery: flag a difficult airway and cervical cord risk early, review prior anaesthesia, mouth opening, neck mobility, OSA and cardiac status, and coordinate with experienced paediatric anaesthesia, surgery and ENT. Maintain neutral cervical alignment and plan extubation and postoperative observation in advance.
Red flags
New gait deterioration, weakness or bladder dysfunction - suspect spinal cord compression.
Stridor at rest, escalating work of breathing or new desaturation - urgent airway and respiratory assessment.
A potentially difficult airway and cervical cord risk before any sedation or surgery.
Normal total urinary GAGs do not exclude MPS IVA - continue subtype-specific enzyme testing when the phenotype is convincing.
A RASopathy with short stature, congenital heart disease (most often pulmonary stenosis), a webbed neck and variable learning difficulties, following autosomal dominant inheritance.
Look for the pattern: short stature, webbed neck, low-set ears and a heart murmur.
Echocardiogram and ECG for pulmonary stenosis or hypertrophic cardiomyopathy.
Check coagulation before any surgery because of a bleeding tendency.
Assess growth and feeding, and consider growth hormone in childhood.
Offer genetic testing of the RASopathy panel and discuss inheritance.
Red flags
Short stature with a heart murmur in a child with a webbed neck
Easy bruising or a bleeding tendency
Unexplained cardiomyopathy in infancy
A collagen type I disorder causing bone fragility, recurrent fractures and blue sclerae, ranging from mild type I to lethal perinatal forms.
Recognise the pattern: fractures, blue sclerae, short stature and a positive family history.
Confirm the diagnosis with COL1A1 and COL1A2 sequencing and collagen studies where indicated.
Assess bone health: spinal imaging, DXA where appropriate, and vitamin D and calcium status.
Treat and support: bisphosphonates in moderate to severe disease, physiotherapy, orthotics and fracture prevention.
Red flags
Multiple unexplained fractures, especially in a non-mobile infant
Bowing of long bones or an abnormal skull shape on antenatal ultrasound
Blue-grey sclerae, dentinogenesis imperfecta or early hearing loss
New back pain or loss of height suggesting vertebral compression
A lethal FGFR3 skeletal dysplasia with severe limb shortening, a narrow thorax and macrocephaly, usually detected on antenatal ultrasound.
Recognise antenatally: marked limb shortening, a narrow thorax and a femur length far below the expected range.
Confirm the diagnosis with FGFR3 testing, including the p.Lys650Glu variant in type II.
Plan perinatal care with fetal medicine, neonatology and palliative care teams.
Support the family: genetic counselling, recurrence-risk discussion and bereavement support.
Red flags
Severe limb shortening with a narrow bell-shaped thorax on antenatal ultrasound
Polyhydramnios and reduced fetal movement
Macrocephaly with a cloverleaf skull in type II
Respiratory failure at birth from pulmonary hypoplasia